These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28535704)

  • 1. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
    Avila-Aguero ML; Ulloa-Gutierrez R; Falleiros-Arlant LH; Porras O
    Expert Rev Vaccines; 2017 Jul; 16(7):1-4. PubMed ID: 28535704
    [No Abstract]   [Full Text] [Related]  

  • 2. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
    Naucler P; Galanis I; Morfeldt E; Darenberg J; Örtqvist Å; Henriques-Normark B
    Clin Infect Dis; 2017 Nov; 65(11):1780-1789. PubMed ID: 29020171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
    Guevara JN; Izurieta P; Hoet B
    Expert Rev Vaccines; 2018 Apr; 17(4):283-284. PubMed ID: 29611439
    [No Abstract]   [Full Text] [Related]  

  • 6. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme.
    Wouters I; Van Heirstraeten L; Desmet S; Blaizot S; Verhaegen J; Goossens H; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2018 Jan; 36(1):15-22. PubMed ID: 29180027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
    Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
    Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.
    Lipsitch M; Li LM; Patterson S; Trammel J; Juergens C; Gruber WC; Scott DA; Dagan R
    Vaccine; 2018 Jan; 36(4):473-478. PubMed ID: 29248266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.
    Gurung M; Bijukchhe SM; Hariri P; Voysey M; Kandasamy R; Thorson S; Maskey P; Pandit R; Shrestha B; Gautam MC; Maharjan M; Lama L; Acharya B; Basi R; K C M; O'Reilly P; Shrestha S; Ansari I; Shah GP; Kelly S; O'Brien KL; Goldblatt D; Kelly DF; Murdoch DR; Pollard AJ; Shrestha S
    Pediatr Infect Dis J; 2021 Oct; 40(10):937-943. PubMed ID: 34292271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M
    PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease in Latin America and the Caribbean: Serotype distribution, disease burden, and impact of vaccination. A systematic review and meta-analysis.
    Bardach A; Ruvinsky S; Palermo MC; Alconada T; Sandoval MM; Brizuela ME; Wierzbicki ER; Cantos J; Gagetti P; Ciapponi A
    PLoS One; 2024; 19(6):e0304978. PubMed ID: 38935748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of Streptococcus pneumoniae in children living in southwest China and assessment of a potential protein vaccine, rPfbA.
    Yan Z; Cui Y; Zhou W; Li W; Tan X; Chen W; Zhang J; Jiang Y
    Vaccine; 2019 Jan; 37(5):721-731. PubMed ID: 30611601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2016 Aug; 34(36):4313-20. PubMed ID: 27422342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
    Esposito S; Principi N
    Future Microbiol; 2019 Jul; 14():921-923. PubMed ID: 31373218
    [No Abstract]   [Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.
    Ojal J; Hammitt LL; Gaitho J; Scott JAG; Goldblatt D
    Vaccine; 2017 Aug; 35(35 Pt B):4652-4657. PubMed ID: 28739116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.